Understand · Treat · Recover

Perioperative Chemotherapy

Treatment before and after surgery can address microscopic disease and improve the chance of long-term control in eligible resectable cancers.

For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.

This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.

Chapter 10 of 20

Why treatment may come before surgery

Perioperative means around the time of surgery. Preoperative treatment can shrink the tumour, treat invisible disease and demonstrate how the cancer responds. Postoperative treatment addresses remaining microscopic risk. This is different from treating metastatic disease, even when some medicines overlap. For selected very early cancers, surgery or endoscopic treatment alone may be sufficient.

Understanding FLOT

FLOT contains fluorouracil (5-FU), leucovorin, oxaliplatin and docetaxel. Leucovorin supports the action of 5-FU. A common chemotherapy-only schedule uses four two-week cycles before and four after surgery, with assessment and recovery between phases. Treatment usually involves intravenous medicines and a portable 5-FU infusion pump. The actual dose, supportive medicines and timing are prescribed individually.

What the evidence means

FLOT4 compared perioperative FLOT with older epirubicin-based combinations in resectable gastric/GEJ adenocarcinoma. Median overall survival was 50 versus 35 months in the study groups. This established an important role for FLOT in fit patients; it does not predict an individual survival time or show that every patient can tolerate the regimen.

Who may need a different plan?

Frailty, neuropathy, low nutritional reserve, organ dysfunction or other illnesses may favour a fluoropyrimidine–oxaliplatin doublet, modification or another regionally accepted strategy. Physiological fitness matters more than age alone. MSI-high/dMMR disease deserves specialist discussion because its biology may alter the benefit–risk assessment; immunotherapy-only organ-preservation approaches remain setting-specific and should not be assumed routine.

Adding immunotherapy where approved

MATTERHORN supports perioperative durvalumab with FLOT followed by durvalumab alone. The US FDA approved this approach in November 2025 for adults with resectable gastric/GEJ adenocarcinoma. It is not merely an experimental concept, nor is it automatically suitable or available everywhere. The regimen adds immune-related risks; its use should follow the current national label and multidisciplinary assessment. This approval is not dependent on HER2 positivity.

Practical preparation and reassessment

Discuss a central line, anti-nausea medicines, infection precautions, fluoropyrimidine safety testing according to local standards, and nutrition before treatment. Report fever, persistent diarrhea, mouth ulcers, hand–foot soreness and new tingling promptly. Oxaliplatin can cause cold-triggered symptoms. Scans and clinical review help plan surgery; a normal-looking scan does not prove all cancer has gone. After surgery, reduced intake or complications may delay or limit completion, so the team adapts treatment rather than continuing unsafely.

Key takeaways

Choose perioperative treatment by stage, fitness and current evidence, then reassess through recovery.

Frequently asked questions

Does chemotherapy first mean the cancer is incurable?

No. Perioperative treatment is commonly given with curative intent.

Must every patient receive FLOT?

No. Fitness, stage, biology and preferences affect the choice.

If the scan becomes clear, can surgery be skipped?

Not routinely. Imaging cannot establish a complete pathological response.

Is missing postoperative treatment always failure?

No. Recovery and safety affect what can be delivered; discuss the remaining benefit and options.

Is durvalumab just for metastatic disease?

No. A specific perioperative gastric/GEJ indication exists in some countries.

Can I take supplements during treatment?

Check each product with the team because interactions and nutritional risks vary.

References and further reading